PER 5.13% 7.4¢ percheron therapeutics limited

Ann: Positive PDCO opinion and A$20m Placement, page-39

  1. 13,134 Posts.
    lightbulb Created with Sketch. 1376
    “randomised, double-blind, placebo-controlled study to determine the efficacy, safety, and pharmacokinetic profile of ATL1102 (25 mg and 50 mg) administered once weekly by subcutaneous injection for 52
    weeks in non-ambulatory participants with DMD, to be conducted as a potentially pivotal (approvable) trial with a follow-on open label extension trial. Participants will be randomised to either 25 mg ATL1102,”

    Don’t worry people .. games being played
    ”potentially pivotal (approvable) trial”

    That means 1 trial away from commercialisation..$$$

 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.4¢
Change
-0.004(5.13%)
Mkt cap ! $66.71M
Open High Low Value Volume
7.8¢ 7.8¢ 7.2¢ $78.26K 1.049M

Buyers (Bids)

No. Vol. Price($)
1 5919 7.4¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 156164 2
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.